The new demands for HCV related clinical examinations for DAA treatment
10.3760/cma.j.issn.1009-9158.2019.03.002
- VernacularTitle:直接抗病毒药物治疗对HCV相关分子检测的新需求
- Author:
Dong JI
1
;
Boan LI
;
Guofeng CHEN
Author Information
1. 解放军总医院第五医学中心肝硬化诊疗二中心
- Keywords:
Hepacivirus;
Hepatitis C;
Antiviral agents;
Clinical laboratory techniques
- From:
Chinese Journal of Laboratory Medicine
2019;42(3):155-159
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis C virus (HCV) is one of leading causes for chronic liver diseases, the treatment area has been changed rapidly since direct acting antiviral agents (DAAs) were approved to treat patients with chronic HCV infection. To cure hepatitis in 2030 is the goal set by World Health Organization. However, globally, especially in China, there are still many difficulties needing to be resolved on the cure road of chronic hepatitis C, such as large patient population, high percentage of untreated patients, nonstandard DAA treatment, low efficacy of special groups, and resistance-associated variants in baseline, etc. This comment will focus on the new demands for HCV related clinical examinations for DAA treatment, so as to improve the treatment effectiveness and to help achieve the goal of eliminating viral hepatitis .
